Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. In this review, we evaluated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results